GAMMA Investing LLC Buys 135,286 Shares of argenx SE (NASDAQ:ARGX)

GAMMA Investing LLC raised its position in argenx SE (NASDAQ:ARGX - Free Report) by 53,684.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 135,538 shares of the company's stock after buying an additional 135,286 shares during the quarter. GAMMA Investing LLC owned 0.22% of argenx worth $802,200,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Point72 Europe London LLP acquired a new position in argenx in the 4th quarter valued at $5,839,000. Stephens Inc. AR acquired a new position in argenx in the 4th quarter valued at $310,000. Jones Financial Companies Lllp grew its holdings in argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after buying an additional 61 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in argenx by 10.0% in the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock valued at $4,313,000 after buying an additional 639 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB grew its holdings in argenx by 47.8% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 1,776 shares of the company's stock valued at $1,092,000 after buying an additional 574 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Up 2.1%

argenx stock traded up $11.82 during trading hours on Monday, hitting $585.08. The stock had a trading volume of 217,697 shares, compared to its average volume of 323,119. The stock has a market cap of $35.72 billion, a price-to-earnings ratio of -665.26 and a beta of 0.57. argenx SE has a one year low of $368.57 and a one year high of $678.21. The business's 50 day simple moving average is $586.57 and its 200-day simple moving average is $612.64.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. Research analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ARGX shares. Guggenheim decreased their price objective on argenx from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Baird R W raised argenx from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. JMP Securities set a $699.00 target price on argenx in a report on Wednesday, May 14th. Wells Fargo & Company increased their target price on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Finally, Wedbush restated an "outperform" rating and issued a $715.00 target price on shares of argenx in a research report on Friday, April 11th. One equities research analyst has rated the stock with a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $709.18.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.